444 related articles for article (PubMed ID: 22350713)
1. A progressive mouse model of Parkinson's disease: the Thy1-aSyn ("Line 61") mice.
Chesselet MF; Richter F; Zhu C; Magen I; Watson MB; Subramaniam SR
Neurotherapeutics; 2012 Apr; 9(2):297-314. PubMed ID: 22350713
[TBL] [Abstract][Full Text] [Related]
2. Vocalization deficits in mice over-expressing alpha-synuclein, a model of pre-manifest Parkinson's disease.
Grant LM; Richter F; Miller JE; White SA; Fox CM; Zhu C; Chesselet MF; Ciucci MR
Behav Neurosci; 2014 Apr; 128(2):110-21. PubMed ID: 24773432
[TBL] [Abstract][Full Text] [Related]
3. A Mouse Model to Test Novel Therapeutics for Parkinson's Disease: an Update on the Thy1-aSyn ("line 61") Mice.
Richter F; Stanojlovic M; Käufer C; Gericke B; Feja M
Neurotherapeutics; 2023 Jan; 20(1):97-116. PubMed ID: 36715870
[TBL] [Abstract][Full Text] [Related]
4. Transgenic Mice Expressing Human α-Synuclein in Noradrenergic Neurons Develop Locus Ceruleus Pathology and Nonmotor Features of Parkinson's Disease.
Butkovich LM; Houser MC; Chalermpalanupap T; Porter-Stransky KA; Iannitelli AF; Boles JS; Lloyd GM; Coomes AS; Eidson LN; De Sousa Rodrigues ME; Oliver DL; Kelly SD; Chang J; Bengoa-Vergniory N; Wade-Martins R; Giasson BI; Joers V; Weinshenker D; Tansey MG
J Neurosci; 2020 Sep; 40(39):7559-7576. PubMed ID: 32868457
[TBL] [Abstract][Full Text] [Related]
5. Social Cognition Impairments in Mice Overexpressing Alpha-Synuclein Under the Thy1 Promoter, a Model of Pre-manifest Parkinson's Disease.
Magen I; Torres ER; Dinh D; Chung A; Masliah E; Chesselet MF
J Parkinsons Dis; 2015; 5(3):669-680. PubMed ID: 25588356
[TBL] [Abstract][Full Text] [Related]
6. The small molecule alpha-synuclein misfolding inhibitor, NPT200-11, produces multiple benefits in an animal model of Parkinson's disease.
Price DL; Koike MA; Khan A; Wrasidlo W; Rockenstein E; Masliah E; Bonhaus D
Sci Rep; 2018 Nov; 8(1):16165. PubMed ID: 30385782
[TBL] [Abstract][Full Text] [Related]
7. Cognitive deficits in a mouse model of pre-manifest Parkinson's disease.
Magen I; Fleming SM; Zhu C; Garcia EC; Cardiff KM; Dinh D; De La Rosa K; Sanchez M; Torres ER; Masliah E; Jentsch JD; Chesselet MF
Eur J Neurosci; 2012 Mar; 35(6):870-82. PubMed ID: 22356593
[TBL] [Abstract][Full Text] [Related]
8. Alpha-synuclein pathology, microgliosis, and parvalbumin neuron loss in the amygdala associated with enhanced fear in the Thy1-aSyn model of Parkinson's disease.
Torres ERS; Stanojlovic M; Zelikowsky M; Bonsberger J; Hean S; Mulligan C; Baldauf L; Fleming S; Masliah E; Chesselet MF; Fanselow MS; Richter F
Neurobiol Dis; 2021 Oct; 158():105478. PubMed ID: 34390837
[TBL] [Abstract][Full Text] [Related]
9. Intranasal carnosine attenuates transcriptomic alterations and improves mitochondrial function in the Thy1-aSyn mouse model of Parkinson's disease.
Bermúdez ML; Skelton MR; Genter MB
Mol Genet Metab; 2018 Nov; 125(3):305-313. PubMed ID: 30146452
[TBL] [Abstract][Full Text] [Related]
10. The novel adaptive rotating beam test unmasks sensorimotor impairments in a transgenic mouse model of Parkinson's disease.
Gerstenberger J; Bauer A; Helmschrodt C; Richter A; Richter F
Behav Brain Res; 2016 May; 304():102-10. PubMed ID: 26880341
[TBL] [Abstract][Full Text] [Related]
11. Behavioral effects of dopaminergic agonists in transgenic mice overexpressing human wildtype alpha-synuclein.
Fleming SM; Salcedo J; Hutson CB; Rockenstein E; Masliah E; Levine MS; Chesselet MF
Neuroscience; 2006 Nov; 142(4):1245-53. PubMed ID: 16934409
[TBL] [Abstract][Full Text] [Related]
12. Region specific mitochondrial impairment in mice with widespread overexpression of alpha-synuclein.
Subramaniam SR; Vergnes L; Franich NR; Reue K; Chesselet MF
Neurobiol Dis; 2014 Oct; 70():204-13. PubMed ID: 25016198
[TBL] [Abstract][Full Text] [Related]
13. A pilot trial of the microtubule-interacting peptide (NAP) in mice overexpressing alpha-synuclein shows improvement in motor function and reduction of alpha-synuclein inclusions.
Fleming SM; Mulligan CK; Richter F; Mortazavi F; Lemesre V; Frias C; Zhu C; Stewart A; Gozes I; Morimoto B; Chesselet MF
Mol Cell Neurosci; 2011 Mar; 46(3):597-606. PubMed ID: 21193046
[TBL] [Abstract][Full Text] [Related]
14. Parkinson's disease and alpha synuclein: is Parkinson's disease a prion-like disorder?
Olanow CW; Brundin P
Mov Disord; 2013 Jan; 28(1):31-40. PubMed ID: 23390095
[TBL] [Abstract][Full Text] [Related]
15. Depopulation of dense α-synuclein aggregates is associated with rescue of dopamine neuron dysfunction and death in a new Parkinson's disease model.
Wegrzynowicz M; Bar-On D; Calo' L; Anichtchik O; Iovino M; Xia J; Ryazanov S; Leonov A; Giese A; Dalley JW; Griesinger C; Ashery U; Spillantini MG
Acta Neuropathol; 2019 Oct; 138(4):575-595. PubMed ID: 31165254
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of Carnosine Intervention in the Thy1-aSyn Mouse Model of Parkinson's Disease.
Bermúdez ML; Seroogy KB; Genter MB
Neuroscience; 2019 Jul; 411():270-278. PubMed ID: 31125602
[TBL] [Abstract][Full Text] [Related]
17. α-synuclein expression from a single copy transgene increases sensitivity to stress and accelerates neuronal loss in genetic models of Parkinson's disease.
Cooper JF; Spielbauer KK; Senchuk MM; Nadarajan S; Colaiácovo MP; Van Raamsdonk JM
Exp Neurol; 2018 Dec; 310():58-69. PubMed ID: 30194957
[TBL] [Abstract][Full Text] [Related]
18. Genetic mouse models of Parkinson's disease The state of the art.
Magen I; Chesselet MF
Prog Brain Res; 2010; 184():53-87. PubMed ID: 20887870
[TBL] [Abstract][Full Text] [Related]
19. GBA haploinsufficiency accelerates alpha-synuclein pathology with altered lipid metabolism in a prodromal model of Parkinson's disease.
Ikuno M; Yamakado H; Akiyama H; Parajuli LK; Taguchi K; Hara J; Uemura N; Hatanaka Y; Higaki K; Ohno K; Tanaka M; Koike M; Hirabayashi Y; Takahashi R
Hum Mol Genet; 2019 Jun; 28(11):1894-1904. PubMed ID: 30689867
[TBL] [Abstract][Full Text] [Related]
20. Intranasal Carnosine Mitigates α-Synuclein Pathology and Motor Dysfunction in the Thy1-aSyn Mouse Model of Parkinson's Disease.
Brown JM; Baker LS; Seroogy KB; Genter MB
ACS Chem Neurosci; 2021 Jul; 12(13):2347-2359. PubMed ID: 34138535
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
